heather m snyder ph d senior director medical amp
play

Update on Alzheimers Research for NARFE Heather M. Snyder, Ph.D. Senior Director, Medical & Scientific Relations Alzheimers Association Types of Dementia 2 What is Alzheimers? Alzheimers is a universally fatal brain disease

0 downloads 3 Views 1,73 MB Size Report
  1. Update on Alzheimer’s Research for NARFE Heather M. Snyder, Ph.D. Senior Director, Medical & Scientific Relations Alzheimer’s Association

  2. Types of Dementia 2

  3. What is Alzheimer’s? • Alzheimer’s is a universally fatal brain disease • Alzheimer’s has a gradual onset • Alzheimer’s is progressive, meaning it gets worse over time • The vast majority of people develop “late onset” Alzheimer’s dementia (over age 65) 3

  4. Impact of Alzheimer’s Dementia Continues To Grow $ 1.1 TRILLION IN 2050 2017 Alzheimer’s Association Facts & Figures 4

  5. 5

  6. Alzheimer’s Association Funding the Future • World’s largest, most impactful non-profit funder of research; $380M since 1982 • Today, more than $100M active in 18 countries • Focus on innovative ideas from early career investigators • Emerging areas & gaps 6

  7. Significant Advances Made Possible Because of NARFE! • Over $12 million funding 71 innovative scientific projects • Funding gaps & emerging areas, advancing the science to the next level • Research funded spans the full spectrum of science to better understand & treat Alzheimer’s disease • NARFE funded researchers are significantly advancing our understanding of disease, developing tools to improve diagnosis, and exploring diverse avenues for potential therapies 7

  8. Both Association Funding and Federal Research Funding are Critical Federal Funding Association Funding  Larger in scale  Quickly deployed  Breadth of coverage  Precisely targeted  Longer term  Global scope sustainability  Higher risk tolerance Association and federal research f unding don’t compete… they complement each other 8 8

  9. History of Alzheimer’s Disease tangles plaques 9

  10. Continuum of Alzheimer’s Disease Alzheimer’s disease Normal Adapted from Sperling et al. 2011 10

  11. Advances in Early Detection Targeted biochemical Genetics Protein production & clearance rates Epidemiology Proteomics Structural Neuroimaging Neuropsychometric tests PET Imaging 11

  12. NARFE Investigators Advancing Early Detection • 2015 award to Min Shi, Ph.D. (University of Washington) to study changes of tau as potential plasma biomarker of Alzheimer's • 2011 award to Joseph Goveas, MD (Medical College of Wisconsin) to investigate different kinds of imaging depressed adults at risk for Alzheimer’s • 2009 award to Barbara B. Bendlin, PhD (UW, Madison) to understand changes in brain vascular systems in middle age adults at risk by imaging 12

  13. Pathway to Approval for Drug Development 75 Adapted from PhRMA Annual report 13

  14. NARFE Investigators Exploring Diverse Potential Therapy Avenues • 2011 award to David Cribbs, PhD (UC, Irvine) on links of Cerebral Amyloid Angiopathy, inflammation & hypertension and 2012 award to Michael Agadjanyan, Ph.D. (Institute for Molecular Medicine) on immune response to vaccines; partnering together on a phase 1 trial • 2014 award to Charbel Moussa, Ph.D. (Georgetown University) on effects of Nilotinib on tau clearance in Alzheimer’s; funded by NIH and recruiting for participants now 14

  15. Current Landscape of Clinical Trials for Alzheimer’s & Dementia Phase II Phase III Phase I 75 Total Trials 112 Total Trials 37 Total Trials  49 experimental  79 experimental  14 registration trials  5 for agitation or sleep medications medications  3 medical devise  7 medical devise  9 academic trials  9 diagnostic trials  6 diagnostic trials  2 medical devise  14 experimental  20 experimental  3 diagnostic trials  4 trials for non-AD medications for non- medications for non-AD AD dementias dementias dementias 13 Clinical trials with Computerized Devises for Alzheimer’s and Cognitive Decline for detection and / or cognitive training. As of 2/2017 15

  16. Questions On Underlying Biology of Alzheimer’s in Women and in Men • X/ Y chromosomes genetic links disease related biology • Differences in brain function & networks as it relates to disease • Links of hormone levels (i.e. perimenopause) & energy metabolisms (i.e. shift from glucose to ketone energy usage) • Lifestyle factors (i.e. stress, metabolism, sleep) related to risk and/or reduced risk 16

  17. Underlying Biology of Alzheimer’s in Women and in Men • X/ Y chromosomes genetic links disease related biology • Differences in brain function & networks as it relates to disease • Links of hormone levels (i.e. perimenopause) & energy metabolisms (i.e. shift from glucose to ketone energy usage) • Lifestyle factors (i.e. stress, metabolism, sleep) related to risk and/or reduced risk 17

  18. Continuum of Alzheimer’s Disease Alzheimer’s disease Normal Adapted from Sperling et al. 2011 18

  19. Collaboration for Alzheimer’s Prevention 19

  20. What should I be doing now? 20

  21. If we delay onset of Alzheimer’s by 5 years… 21

  22. Thank you You are making a difference towards seeing a World without Alzheimer’s! 22

  23. 23

Recommend Documents


medical laboratory technology
Medical Laboratory Technology

Medical Laboratory Technology https://www.pcc.edu/programs/medical-lab/

hans westergren m d ph d senior consultant and medical
Hans Westergren M.D., Ph.D. Senior

Experiences fro from a a Specializ ized Regional Clin linic for

michigan office for new americans
Michigan Office for New Americans !

Michigan Office for New Americans ! Executive Office of Governor Rick Snyder !

medicaid reform updates
Medicaid Reform Updates Melisa Byrd

Medicaid Reform Updates Melisa Byrd Senior Deputy Director/Medicaid Director

innovative care
INNOVATIVE CARE AND SERVICE MODELS

INNOVATIVE CARE AND SERVICE MODELS WEDNESDAY, APRIL 6 10:30 AM Heather

senior pwp network
Senior PWP Network 23 January 2018

Yorkshire and the Humber Mental Health Network Senior PWP Network 23 January

senior pwp network
Senior PWP Network 26 September 2017

Yorkshire and the Humber Mental Health Network Senior PWP Network 26

how to provide effective safety net palliative care
How to Provide Effective Safety Net

How to Provide Effective Safety Net Palliative Care Will Kennedy, DO Senior

value of medical director and attending training
VALUE OF MEDICAL DIRECTOR AND

11/18/2016 Susan M. Levy, MD, CMD: Disclosures President AMDA The Society for

heather lorenz msoh cih csp cmlso director ehrs
Heather Lorenz, MSOH, CIH, CSP, CMLSO

Heather Lorenz, MSOH, CIH, CSP, CMLSO Director, EHRS Environmental Health and

the respiratory system
THE RESPIRATORY SYSTEM THE RESPIRATORY

THE RESPIRATORY SYSTEM THE RESPIRATORY SYSTEM VISCERA OF THORACIC CAVITY

osha s crystalline silica rule for construction
OSHAs Crystalline Silica Rule for

6/4/2017 OSHAs Crystalline Silica Rule for Construction Comply by September

pulmonary in service
Pulmonary In-service Bassem Srour, MD,

Pulmonary In-service Bassem Srour, MD, FCCP. Pulmonary, Critical Care &

learning intention
Learning Intention To can identify and

Learning Intention To can identify and name the parts of the human circulatory

ultrafine particles and freeways
Ultrafine Particles and Freeways

Ultrafine Particles and Freeways Yifang Zhu , Ph.D. Assistant Professor

swerf size weighted respirable fraction size weighted
SWeRF Size-Weighted Respirable

SWeRF Size-Weighted Respirable Fraction Size-Weighted Respirable Fraction

investor presentation
Investor Presentation A novel approach

Investor Presentation A novel approach to treating cognitive impairment and

moderator leah levine
MODERATOR: LEAH LEVINE Recruitment

YOUTH ENGAGEMENT IN ALZHEIMERS DISEASE ADVOCACY AND CAREGIVING PANEL

dementia and developmental disabilities supporting
Dementia and Developmental

Dementia and Developmental Disabilities: Supporting Individuals in Maintaining

dementia
Dementia An interprofessional

T HIS CLINICAL TRAINING INITIATIVE IS SUPPORTED BY FUNDING FROM THE A USTRALIAN

the potential for new treatments for alzheimer s disease
The Potential for New Treatments for

The Potential for New Treatments for Alzheimers Disease: Where Are We Headed

the choice of outcome parameters and need for distinct
The choice of outcome parameters and

The choice of outcome parameters and need for distinct assessment tools with